Literature DB >> 14367519

Studies in intravascular coagulation. III. The pathogenesis of serum-induced venous thrombosis.

S WESSLER.   

Abstract

Entities:  

Keywords:  THROMBOPHLEBITIS/experimental

Mesh：

Year:  1955        PMID： 14367519      PMCID： PMC438671          DOI： 10.1172/JCI103114

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  8 in total

1.  Proconvertin content in the blood of newborn full-term and premature infants.

Authors:  S VAN CREVELD; C A VAN DER MEIJ; P VERSTEEG; E T VERSTEEGH
Journal:  Etudes Neonatales       Date:  1954-03

2.  Factor VII (SPCA): its physiopathologic significance.

Authors:  P DE NICOLA
Journal:  Blood       Date:  1953-10       Impact factor: 22.113

3.  Studies in intravascular coagulation. I. Coagulation changes in isolated venous segments.

Authors:  S WESSLER
Journal:  J Clin Invest       Date:  1952-11       Impact factor: 14.808

4.  Studies in intravascular coagulation. II. A comparison of the effect of dicumarol and heparin on clot formation in isolated venous segments.

Authors:  S WESSLER
Journal:  J Clin Invest       Date:  1953-07       Impact factor: 14.808

5.  [Umbilical cord blood; complete study of its coaguability, comparison with maternal blood].

Authors:  M J LARRIEU; J P SOULIER; A MINKOWSKI
Journal:  Etudes Neonatales       Date:  1952-02

6.  The labile factor of prothrombin conversion: its consumption under normal and pathological conditions affecting blood coagulation.

Authors:  B ALEXANDER; R GOLDSTEIN; G LANDWEHR
Journal:  J Clin Invest       Date:  1951-03       Impact factor: 14.808

7.  [AC globulin and SPCA: two plasma factors in the conversion of prothrombin; clinical and biological study and review].

Authors:  B ALEXANDER
Journal:  Rev Hematol       Date:  1952

8.  Behaviour of factor VII and prothrombin in late pregnancy and in the newborn.

Authors:  A LOELIGER; F KOLLER
Journal:  Acta Haematol       Date:  1952-03       Impact factor: 2.195
  8 in total
  29 in total

1.  ACTIVATION PRODUCT, FACTOR IX, SERUM THROMBOTIC ACCELERATOR ACTIVITY, AND SERUM-INDUCED THROMBOSIS.

Authors:  D DEYKIN; S WESSLER
Journal:  J Clin Invest       Date:  1964-02       Impact factor: 14.808

2.  THROMBOSIS ASSOCIATED WITH MOBILIZATION OF FATTY ACIDS.

Authors:  J C HOAK; J C POOLE; D S ROBINSON
Journal:  Am J Pathol       Date:  1963-12       Impact factor: 4.307

3.  THE ROLE OF LIPOPROTEINS IN THE PRODUCTION OF HYPERCOAGULABILITY: A NEW CONCEPT.

Authors:  R M HOWELL; G B SCOTT
Journal:  Br J Exp Pathol       Date:  1964-12

4.  [THE PHYSIOLOGIC INHIBITORS OF BLOOD COAGULATION IN PATHOLOGICALLY INCREASED COAGULABILITY IN VIVO. II. SERUM INFUSION INTO THE BLOOD STREAM].

Authors:  K SCHIMPF; A CIBELIUS; R MARDINI
Journal:  Klin Wochenschr       Date:  1964-07-01

5.  ATHEROSCLEROSIS, HYPERLIPAEMIA AND HYPOCOAGULABILITY IN THE RAT. AN EXPERIMENTAL STUDY.

Authors:  G B SCOTT
Journal:  Br J Exp Pathol       Date:  1964-02

6.  ACUTE HEPATIC NECROSIS AND BLOOD COAGULATION. AN IN VIVO APPROACH.

Authors:  G B SCOTT; R M HOWELL
Journal:  Br J Exp Pathol       Date:  1964-02

7.  STRUCTURE OF THROMBI PRODUCED BY INJECTIONS OF FATTY ACIDS.

Authors:  J C HOAK
Journal:  Br J Exp Pathol       Date:  1964-02

8.  LETHALITY OF INTRAVASCULAR INJECTIONS OF SPLEEN AND LIVER CELLS.

Authors:  H M KAUFFMAN; R F CLARK; L M FISHER; D M HUME
Journal:  Ann Surg       Date:  1964-02       Impact factor: 12.969

9.  The investigation of three cases of phlebothrombosis using a bioassay method.

Authors:  G B SCOTT
Journal:  Br J Exp Pathol       Date:  1963-06

10.  The thrombotic activity of activation product.

Authors:  E S HENDERSON; S L RAPAPORT
Journal:  J Clin Invest       Date:  1962-02       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.